KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) EBITDA (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed EBITDA for 15 consecutive years, with -$3.9 million as the latest value for Q4 2025.

  • On a quarterly basis, EBITDA fell 118.39% to -$3.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$62.3 million, a 176.27% decrease, with the full-year FY2025 number at -$62.3 million, down 176.27% from a year prior.
  • EBITDA was -$3.9 million for Q4 2025 at Supernus Pharmaceuticals, up from -$60.2 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $40.8 million in Q3 2024 to a low of -$60.2 million in Q3 2025.
  • A 5-year average of $7.3 million and a median of $7.1 million in 2021 define the central range for EBITDA.
  • Peak YoY movement for EBITDA: tumbled 255.01% in 2023, then skyrocketed 2249.1% in 2024.
  • Supernus Pharmaceuticals' EBITDA stood at $6.1 million in 2021, then soared by 463.04% to $34.3 million in 2022, then plummeted by 102.9% to -$996000.0 in 2023, then surged by 2249.1% to $21.4 million in 2024, then tumbled by 118.39% to -$3.9 million in 2025.
  • Per Business Quant, the three most recent readings for SUPN's EBITDA are -$3.9 million (Q4 2025), -$60.2 million (Q3 2025), and $12.1 million (Q2 2025).